Introduction
Angiopoietins (Ang) are a group of growth factors that affect the growth of endothelial cells. 1 So far, four members (Ang1, Ang2, Ang3 and Ang4) belonging to this family have been characterized. 2, 3 All of them bind to the Tie2 (tyrosine kinase with immunoglobulin and epidermal growth factor homology domain) receptor. Tie2 is expressed predominantly on endothelial cells, hematopoietic cells or their precursors, and is required for normal vascular development. 4 Angs are composed of two distinct regions, a coiled-coil domain and a fibrinogen-like domain. Ang1 and Ang2 coiled coil domains mediate distinct homo-oligomerization patterns and fibrinogen-like domains mediate ligand activity. 5 Significance of Tie2 and Angs in angiogenesis and vascular development has been studied in genetically altered mice. Transgenic mice overexpressing Ang1 had more and larger vessels in their skin, 6 while transgenic overexpression of Ang2 disrupts blood vessel formation in mouse embryo. 7 Tie2 null mice died between E9.5 and E10.5. These mice had cardiac defects and failure of capillary invasion into neuroectoderm. 8 Targeted disruption of Ang1 gene resulted in embryonic death at E12. 5, 9 while most of the mice with targeted disruption of Ang2 gene died perinatally or within a couple of days after birth but some survived to adulthood. 10 These studies show that Ang1 plays an important role in stabilization and maturation of blood vessels in pre-and postnatal angiogenesis. It is also known that Ang1 can reduce permeability of endothelial cells induced by several stimuli, such as vascular endothelial growth factor (VEGF), histamine and inflammatory cytokines. 11 A combination of Ang1 and VEGF-A gene delivery in ischemic skeletal muscle promotes neovascularization 12 and could prevent undesirable effects induced by VEGF. 13, 14 However, no results are available about the effect of Ang1 in the perivascular compartment, which is clinically accessible target during vascular surgery and operations based on needle injection catheters.
Perivascular gene transfer has been used in preclinical and clinical studies for therapeutic angiogeneis and to inhibit neointima formation. [15] [16] [17] It has been used to improve vein graft survival. An ongoing clinical trial is using biodegradable collagen collars as a reservoir to deliver AdvVEGF-D for the prevention of vascular access stenosis. 16 Perivascular gene delivery of VEGF-A is also useful for promoting therapeutic angiogenesis in ischemic myocardium. 17 Application methods, such as perivascular collars or sheaths, needle injection catheters and biodegradable gels can be used to deliver vectors directly into the adventitia. 18 Periadventitial gene transfer has therefore specific clinical applications. As no data are available from Ang1 gene transfer to perivascular tissue, we decided to investigate the angiogenic potential of Ang1 in vivo after adenovirus-mediated gene transfer in perivascular tissue. A role of endogenous VEGF-A in Ang1-mediated angiogenesis in ischemic conditions has been proposed, but there is insufficient data to support this hypothesis. Therefore, we also decided to evaluate the potential role of endogenous VEGF-A in Ang1-mediated angiogenesis.
Results
Transgene expression and Tie2 receptor expression 
Angiogenic responses
Ang1 transduction resulted in the formation of CD-31-positive tubular structures in the adventitia. Large vascular channels along with some smaller channels were observed (Figure 3a) . Red blood cells were present in the lumen of the CD-31 positive neovessels. By CD-31 and smooth muscle a-actin double immunostainings, we were able to identify the presence of pericytes in many of the newly formed vessels (Figure 3b ). When Ang1 was given in combination with VEGFR-1-Ig, there was a decrease in the number of neovessels and their lumens were not well formed (Figure 3c ). VEGFR-1-Ig and LacZ control showed normal histology (Figure 3d ,e).
The number of capillaries per mm 2 (126.4744.6) in the adventitia of the Ang1 transduced arteries was significantly (Po0.05) higher than that in the LacZ (9.472.6) transduced controls ( Figure 4a ). The number of capillaries in the adventitia tended to be lower when VEGF-R1-Ig was used with Ang1 (48.8710.2) as compared to Ang1 alone, although the difference was not statistically significant ( Figure 4a ). The number of capillaries in the adventitia of the VEGF-R1-Ig transduced arteries (10.772.3) was significantly (Po0.05) lower than that formed by Ang1 alone. Fluorescence by rhodamine ricinus communis lectin injected systemically was observed in the majority of neovessels formed in the Ang1 transduced arteries indicating that these vessels were well perfused ( Figure 3g ). In the LacZ transduced arteries, rhodamine fluorescence was only seen in vasa vasorum ( Figure 3h ). Rhodamine fluorescence was barely detectable or totally absent from the vessels that were formed when VEGF-R1-Ig was used with Ang1 (data not shown). This indicates a scanty or absent perfusion of those vessels and hence considered as poorly functional vessels.
Macrophage infiltration and neointima formation
Macrophage infiltration in the arterial wall after Ang1 transduction was mild (57.2717.4) and comparable to that of the LacZ (68.8714. 
Discussion
Placement of a hollow collar around blood vessels offers a convenient method for efficient local perivascular gene transfer in vivo. 20 Periadventitial gene transfer of vascular growth factors could potentially be useful to: (a) promote therapeutic angiogenesis in ischemic myocardium and skeletal muscle; (b) inhibit neointima formation in vein grafts; (c) adventitial angiogenesis that can improve vein graft survival and improve surgical outcome. In our previous study we successfully used this model for periadvential gene delivery to compare the angiogenic potential of different VEGFs. 15 In this study we used the collar model for the analysis of the angiogenic effects of Ang1.
Previous studies have shown that Ang1 and Tie2 participate in capillary tube formation and angiogenesis. 6, 9 It has been demonstrated that adenoviral Ang1 gene transfer resulted in the reduction of infarct size and a decrease in the progressive loss of cardiac performance in rats. 21 It has also been reported that after naked plasmid gene transfer Ang1 but not Ang2 augments revascularization in ischemic rabbit hindlimbs. 22 However, there are contradictory findings regarding the ability of Ang1 gene transfer to induce angiogenesis in rabbit skeletal muscles. 23, 24 Recently, it has also been reported that venules in mouse trachea enlarged after AdvAng1 treatment, but the effect was not mediated by VEGF. 25 Adenovirus based vectors are one of the most efficient gene transfer tools used in clinical and preclinical studies as compared to low transduction efficiency of plasmids. 26 Preclinical data for angiogenic response of AdvAng1 in large animals are not available and only a few studies in small animals 21 have been published. This is the first study to show successful angiogenic effect of adenovirus-mediated Ang1 gene delivery in perivascular tissue. Since angiogenic effects may be tissue and vascular bed dependent we tested Ang1 in the periadventitial space, which is a highly accessible compartment 
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for clinical gene transfer applications during vascular surgery and bypass operations. 27 We found a significant increase in the number of neovessels in the adventitia of the Ang1 transduced arteries as compared to the LacZ controls. Large wellformed vessels were seen in the adventitia of the Ang1 transduced arteries. Lectin angiography 28, 15 clearly demonstrated perfusion of these neovessels. The rhodamine ricinus communis injected into the left ventricle of the heart perfused the adventitial neovessels in the Ang1 transduced arteries, indicating the presence of functional blood flow. Recruitment of pericytes into these newly formed vessels suggests their physiological maturity. Recently, it has been reported that there is a significant increase in the pericyte coverage of blood vessels in the Ang1 transduced tumors. 29 Ang1 may be required for interactions between endothelium, surrounding matrix and mesenchyme. 9 One mechanism by which Ang1 may contribute to vascular stability and maturity is by increasing the recruitment of pericytes.
When VEGF-R1-Ig was transduced with Ang1 to block the effects of endogenous VEGF-A, it resulted in a reduced number of neovessels. Although the decrease in the number of neovessels in the adventitia of AdvAng1 with AdvVEGF-R1-Ig transduced arteries was not statistically significant, there was a significant difference in the morphology and perfusion of these vessels. The vessels formed in AdvAng1 with AdvVEGF-R1-Ig transduced arteries were small and poorly perfused as compared to the well-formed and well-perfused vessels seen when AdvAng1 was used alone. Endogenous VEGF-A is therefore required for the development of functional blood vessels after Ang1 gene transfer. This observation provides indirect evidence to support the concept that synergistic effects exist between Ang1 and endogenous VEGF-A. Ang1 gene transfer to tissues deficient in endogenous VEGF-A may therefore result in insufficient angiogenesis and the presence of endogenous VEGF-A seems to be an important contributing factor for the angiogenic effect of Ang1. This finding could explain some of the previous contradictory findings. 22, 25 We recently demonstrated that perivascular gene transfer of VEGF-A could result in significant neoinitma formation as compared to LacZ controls. 30 In contrast, neointima formation seen in this study in Ang1 transduced arteries was comparable to that of LacZ controls. This could be beneficial when considering the use of Ang1 for clinical applications in therapeutic vascular growth. 26 Vein graft survival is dependent on adequate vascularization and patency. Periadventitial angiogenesis using Ang1 could be more advantageous for vein graft survival as it has additional benefit of not exacerbating neointimal hyperplasia. Recently, Ang1 was also reported to protect vessels against the development of arteriosclerosis in cardiac allografts. 31 Edema and inflammation were also reported in the rabbit skeletal muscles after VEGF-A gene therapy. 32 In an earlier study by our group, delivery of the AdvVEGF-A into the periadventitial space of the carotid arteries resulted in a significant increase in inflammatory infiltrates 15 as compared to the controls. However, in the present study, inflammatory responses in the Ang1 transduced arteries were comparable to that seen in the LacZ controls. This is in line with the anti-inflammatory Angiopoietin gene transfer to vascular tissue S Bhardwaj et al properties of Ang1 described previously. 33, 34 Therapeutic angiogenesis using Ang1 either alone or in combination with VEGFs may reduce side effects like edema and inflammation often seen after the VEGF-A transduction. 35 It is concluded that Ang1 is a potentially useful angiogenic factor in the periadventitial compartment especially in the presence of endogenous VEGF-A. AdvAng1 has the added advantage of not causing severe inflammatory reaction or neointima formation seen with AdvVEGF-A gene transfer. These findings along with the observation that Ang1 overexpression can produce leakage-resistant vessels 14 make Ang1 a potential candidate for clinical applications of the therapeutic vascular growth either alone or in combination with VEGFs.
Materials and methods

Experimental animals
In total, 20 New Zealand White rabbits (n ¼ 5 in each group) were used for the study. A midline neck incision was used to expose both the left and right carotid arteries. Biologically inert silastic collar (2 cm in length; Ark Therapeutics Oy, Kuopio, Finland) was placed around each carotid artery. 15, 20 Gene transfer was carried out 3 days after the collar installation by surgically exposing the collars. Adenoviral vectors with a dose of 1 Â 10 9 pfu for each gene encoding human Ang1 and VEGF receptor-1-Ig fusion protein (VEGF-R1-Ig) were used for the study. The VEGFR-1-Ig/adenovirus plasmid, containing the cDNA coding for the first five immunoglobulin-like domains of the human VEGFR-1 fused in-frame with the sequence encoding the Fc-part of the human IgG, was constructed by cloning the VEGFR-1(1-5)-Ig expression cassette, excised by ApaI and partial HindIII digestion from the VEGFR-1(1À5)/pIg plasmid and blunted with T4 DNA polymerase, into the EcoRV site of the pAdCMV plasmid. 36, 37 Animals were divided into four groups: (1) Ang1, (2) Ang1 with VEGF-R1-Ig, (3) VEGF-R1-Ig and (4) LacZ adenovirus as a control. Human clinical grade E1-partial E3 deleted adenoviruses were produced in 293 cells as described. 38 Tip of a fine cannula (no. 24) was inserted into the collar and 250 ml of each gene transfer solution was injected through the cannula into the collar whereafter tissue glue (Tisseel Duo Quick; Baxter, Austria) was used to seal the collar. Arteries were analyzed for the effects of gene transfer 7 days after the transduction. To verify perfusion of the newly formed vessels we injected rhodamine ricinus communis agglutinin (Vector Laboratories; dose 0.3 mg/kg dissolved in 10 ml of saline) in the left ventricle of the rabbits after thoracotomy 10 min before killing.
Histology
Transduced segment of the carotid artery was dissected and processed as described. 15 Immunohistochemistry for paraffin sections was carried out with avidin biotinhorseradish peroxidase (Vector Laboratories) with DAB (Zymed) as a substrate. The following mouse monoclonal antibodies (mAb) were used for immunostainings: endothelium, mAb CD31 (DAKO, dilution 1:50); macrophages, mAb RAM-11, (DAKO, dilution 1:100); mAb VEGF-A (C-1 antibody # SC-7269, Santa Cruz Biotechnology 1:200); mAb against a-smooth muscle actin (# A2547, clone 1A4, Sigma, 1:800); for immunostainings of Angiopoietins and Tie2 polyclonal antibodies against Ang1 (goat poly IgG antibody # SC6319, Santa Cruz Biotechnology dilution 1:100) and Tie2 (anti-h Tie-2, goat IgG, R&D Systems # AF313, 1:100) were used. For fluorescent microscopy, sections from carotid arteries were deparaffinized and rehydrated, whereafter they were mounted with DAPI (Vectashield-Vector Laboratories) and observed under fluorescent microscope (Olympus AX-70).
Morphometry and image analysis
Morphometry and image analysis were carried out using analySIS (Soft Imaging System Gmbh, Germany) software with Olympus AX70 microscope (Olympus Optical, Tokyo Japan). CD-31 positive vessels, which had a fully formed lumen, were counted in four randomly selected fields with an average area of 0.145 mm 2 /field. Data were transformed to the mean number of capillaries/ mm.
2 RAM-11 positive macrophages were also counted in four randomly selected nonoverlapping fields and results were transformed to the number of macrophages/mm 2 . The total areas of intima and media for individual arteries were measured and expressed as a ratio.
ELISA ELISA (Quantikine-R&D Systems) was used to detect the presence of endogenous VEGF-A protein in tissue fluids collected from collars at the time of sacrifice.
RT-PCR
Total RNA was extracted from carotid artery segments using Trizol reagent (Gibco-BRL) and 2 mg of RNA was used for cDNA synthesis. Primers (20 pmol each) for Ang1 and VEGF-R1-Ig are shown in Table 1 . The forward primer for VEGF-R1-Ig was selected from the VEGFR-1 coding region. The 5 0 primer for Ang1 was selected from the CMV promoter, the 3 0 primer was selected from the coding region. Dynazyme polymerase (Finnzymes, Finland) was used for the amplification.
Statistical analysis
Mean values7s.d. were calculated for neovessel formation and macrophage infiltration. Nonparametric Kruskal-Wallis test was used to analyze the data and post hoc test for statistically significant results in KruskalWallis test was used to calculate differences between the groups. 39 SPSS-12 software (SPSS Inc.) was used 
